AzurRx BioPharma, Inc.’s (NASDAQ:AZRX) interview with James Sapirstein, Chairman & CEO

0
21

See the full episode at: https://newtothestreet.com/new-to-the-street-july-11-2021-innd-simplicity-esports-globex-data-fandom-sports-winston-gold-strikeforce-sukai

James Spairstein, Chairman & CEO of AzuRx BioPharma (NASDAQ:AZRX), back again on the show, talking about AZRX’s biopharmaceutical products and therapies. He gives an updated and comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, he provides an update on AZRX’s FDA Phase 2 clinical trials on its lead therapeutic candidate, MS1819 – a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/channel/UCceRKKS0QUfXlKUPBoxdTHQ

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://newtothestreet.com/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list

LEAVE A REPLY

Please enter your comment!
Please enter your name here